A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Key Inclusion Criteria:

• Patients with involvement of at least 2 anatomical areas at screening and baseline
• Patients need to have an IGA hand and foot score of 3 or 4 (moderate-to-severedisease) at screening and baseline
• Patients with documented recent history (within 6 months before the screening visit)of inadequate response of atopic hand and foot dermatitis to topical medication(s)
• Patients meet the diagnosis criteria for atopic dermatitis (AD)
• Provide informed consent/assent signed by study patient or legally acceptablerepresentative
• Patients need to have been compliant with the skin protection measures through theentire duration of the screening period

Key Exclusion Criteria:

• Treatment with dupilumab in the past
• Patients with a positive patch test reaction that are deemed to be clinically relevantas the current cause of the hand and foot dermatitis
• Patients with documented exposure to irritants believed to be a predominant cause ofthe current hand and foot dermatitis
• Treatment with systemic corticosteroids or non-steroidal immunosuppressive drugswithin 4 weeks prior to baseline
• Known history of HIV/HBV/HCV infection
• Pregnant or breastfeeding women or planning to become pregnant or breastfeed duringthe patient's participation in this study
• Women of childbearing potential (WOCBP) who are unwilling to practice highly effectivecontraception prior to the initial dose/start of the first treatment and during thestudy NOTE: Other protocol defined inclusion / exclusion criteria apply